A phase III comparison of high dose ARA-C (HIDAC) versus HIDAC plus mitoxantrone in the treatment of first relapsed or refractory acute myeloid leukemia

Chatchada Karanes, Frederick R. Appelbaum, David R. Head et al.|Leukemia Research|1999

Cited by 88